Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield

About this update from Cannara Biotech, Inc.

[{"type":"text","content":"Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at ValleyfieldExpanded credit facility to fund initial post-harvest buildout at Valleyfield, supporting the Company’s long-term goal of reaching 100,000 kg annual capacity\n\n\n\n MONTREAL, Aug. 21, 2025 (GLOBE NEWSWIRE) --\n \n Cannara Biotech Inc.\n \n (“\n \n Cannara\n \n ”, “the\n \n Company\n \n ”, “\n \n us\n \n ” or “\n \n we\n \n ”) (\n \n TSXV: LOVE\n \n ) (\n \n OTCQB: LOVFF\n \n ) (\n \n FRA: 8CB0\n \n ), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce amendments to its existing credit facility with Bank of Montreal (“\n \n BMO\n \n ”) acting as administrative agent, lead arranger, syndication agent and sole bookrunner (the “\n \n Restated Credit Facility\n \n ”), including a $10 million upsize to support strategic capital investments at its Valleyfield facility.\n \n\n “These amendments to our credit facility with BMO reflect the confidence in Cannara’s growth strategy and operational performance,” said Zohar Krivorot, President & CEO of Cannara.\n \n\n “With improved financial flexibility and reduced financing costs, we are well positioned to execute the expansion of our Valleyfield facility and deliver sustained value to our shareholders. Cannara remains committed to maintaining a strong balance sheet while investing in strategic initiatives that support long-term profitable growth,” added Nicholas Sosiak, Chief Financial Officer of Cannara.\n \n\n\n\n $10 Million Capital Expenditures Facility\n \n\n\n\n The Restated Credit Facility includes the addition of a $10 million committed delayed capital expenditures debt facility (the “\n \n Capital Expenditures Facility\n \n ”). The Capital Expenditures Facility is available by way of multiple draws until July 2026 with a 10-year amortization schedule, repaid in quarterly instalments of unblended payments of principal and interest, with the remaining balance due on December 31, 2027.\n \n\n The new Capital Expenditures Facility will fund the initial phase of Cannara’s post-harv...

More updates from Cannara Biotech, Inc.